Drug Profile
Chikungunya vaccine live - Valneva
Alternative Names: Chikungunya vaccine, live; Chikungunya virus vaccine - Valneva; IXCHIQ; Live-attenuated Chikungunya Vaccine - Valneva; Live-attenuated CHIKV - Valneva; Single-Shot Chikungunya Vaccine - Valneva; VLA-1553Latest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Valneva
- Developer Instituto Butanan; Valneva
- Class Attenuated vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Chikungunya virus infections
Most Recent Events
- 04 Mar 2024 Valneva intends to launch VLA 1553 for Chikungunya virus infections (Prevention) in the USA in December 2024
- 04 Mar 2024 Valneva expects the decision on regulatory submissions by European Medicine Agency (EMA) for VLA 1553 in Europe in the mid-2024
- 29 Feb 2024 US CDC Advisory Committee (ACIP) recommends use of VLA 1553 for Chikungunya virus infections